Rheumatoid arthritis | JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis? | rheumatology.medicinematters.com
Frontiers | Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 - ScienceDirect
The Future of JAK Inhibitors - Deallus Strategic Intelligence Consultancy
Strong Commitment' Made to JAK Inhibitor Hair Loss Treatment Development
Pharmacologic inhibition of JAK-STAT signaling promotes hair growth | Science Advances
Jakinibs for Rheumatoid Arthritis Treatment
Topical JAK inhibitor - An effective treatment for facial vitiligo
Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus | Annals of the Rheumatic Diseases
EULAR 2022
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours | British Journal of Cancer
First alopecia treatment for autoimmune disorder that causes sudden hair loss approved by the FDA
JAK inhibitors for the treatment of autoimmune and inflammatory diseases - ScienceDirect
Dermatology Risks Are Likely Different for JAK Inhibitors
Frontiers | Emerging Topical and Systemic JAK Inhibitors in Dermatology
JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency | NEJM
JAK Inhibitors for Eczema Treatment | Gladskin
Targeting the JAK-STAT pathway in the treatment of 'Th2-high' severe asthma | Future Medicinal Chemistry
JAK Inhibitors Are Coming and They Are the Biggest Eczema Development in Years | National Eczema Association
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
Alopecia areata treatment: a role involving Janus Kinase (JAK) inhibitors
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib - eBioMedicine
JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
The Potential of JAK/STAT Pathway Inhibition as a New Treatment Strategy to Control Cytokine Release Syndrome in COVID-19 | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage
Oral surveillance and JAK inhibitor safety: the theory of relativity | Nature Reviews Rheumatology
